Are Psychedelics the Secret for Coma Patients? (CRT) Coma Resurrection Therapy: A Novel Intervention.
The goal of Transcendent Therapeutics, Inc is to pursue the discovery and development of therapeutic potential towards (CRT) Coma Resurrection and pulling patients out of this lethal situation. We are conducting Research for salubrious therapeutics to enhance treatments for Coma Resurrection.
Most fundamentally we would like to see the association of neuron signals to the brain receptors to evaluate the “Brain death, Consciousness, Sub-consciousness and comparing with awareness as well as deep sleep.” This is intended to understand the therapeutic benefits of nano molecule formulations of selective compounds such as Psilocybin, Ketamine, Ibogaine, LSD, DMT, MDMA, Cannabinoid, etc., to support and conduct multi façade research and development and to validate the need and efficacy of these compounds and their potential therapeutic benefits for coma and many unmet medical needs.
The psychedelic psychotherapy panel will discuss the latest understandings of how different psychedelic compounds and their respective therapeutic approaches are proving to be better than others for treating variety of indications. We will be talking with patients who have undergone treatment using everything from DMT aka “The Spirit Molecule” for addictions, to ketamine for PTSD and psilocybin for end of life anxiety. We will also be diving deeper and learning from the subject matter experts who help facilitate these therapies to explore the successful aspects and short comings of the various approaches. We’ll explore perspectives from both ends of the spectrum, the western science based clinical approach of Field Trip, compared to other approaches offered by the Tripmaps platform, including those of a practitioner who speaks the power of the traditional ceremonial approach.
Moderator – Tamara Hirsh
This session will review the different forms of intellectual property that are available to protect innovations in the fast growing field of psychedelics. In particular, this session will provide a detailed look at patenting psychedelic inventions and answer several questions:
- How important is it to secure a priority date for a new invention and when should a patent application be filed?
- What types of inventions can be protected – new derivatives; extraction of actives; medical use?
- What are the requirements for patentability?
In the last two years, dozens of approvals for psychedelic-assisted therapies have been approved for use by patients under the care of psychologists, psychiatrists, clinical counsellors, social workers, general practitioners, and nurses. Specifically, psilocybin has been a molecule of interest that has been a focal point to these alternative treatments, with patient access that falls under a Section 56(1) exemption under Part J of the Food and Drugs Act. From a commercialization standpoint, what licence type is required to prepare a regulated compound such as psilocybin for patients and what specific activities can be performed? What are the site-specific requirements? What evidence do we have to show that controlled substances like psilocybin may follow a similar path towards medicinal use that cannabis has taken? What is the potential for business in psychedelic mushrooms within the applicable legislation and what aspects can be leveraged to further the rate of company success? All this and more will be covered in this informative session.
Psychedelic substances have been around for millenia used by cultures across the globe as medicines and in ceremonies. Most were legal in North America as medicines or in medical research until the 1970’s – 1980’s until the racist and cultural control tactics of the War on Drugs pushed the use of these medicines underground. Now thanks to the persevering work of researchers, scientists, First Nations and therapists from all backgrounds we see these medicines returning to use for PTSD, depression, anxiety, eating disorders, addiction and more. Join Dr. Pamela Kryskow to review a survey of where we are at with these medicines in Canada.
Industry analysts are bullish about the financial potential of the psychedelic drug market, predicting North American sales of almost $7 billion by 2027. A continuing search for new and effective treatments for burgeoning mental illnesses fuels the confidence. On the other hand, new medicinal drugs can face more regulatory roadblocks than recreational ones. This panel, representing some of the most active companies in psychedelic research and development, will come up with a realistic timetable for the full greenlight for licensed psychoactive healing.
Moderator – Katie Pringle
Scientists studying the clinical applications of psychedelics inevitably find their way to ayahuasca shamanism and the role of natural mind-altering substances in Indigenous spirituality and religious practice. In a field of study where science and religion can truly co-exist, researchers and non-Indigenous people must be mindful of honouring the traditions of sacred plants as they attempt to build a bridge between Native cultures and the efficacy of their medicine. This session will consider the traditional use of psychedelics and the reciprocity that must come with adapting it.
Some jurisdictions have already moved toward legalization of medical use of psychedelics. And the wellness community, investors and researchers are thinking positively about imminent wide acceptance. Upcoming breakthroughs may involve court challenges, or changes in existing legislation. Canada has already opened the door for access for end-of-life care, and therapists are seeking to expand the latitude they’ve been given. Once prohibition is past, then a full-fledged regulatory landscape will replace it, covering intellectual property, inspection, quality control, distribution, etc. This panel will look ahead to a legal, regulated future for psychedelics.
Moderator – Sam Riches
In 1956 psychiatrist and superintendent of the Provincial Mental Hospital in Saskatchewan, Canada Humphry Osmond, first used the word ‘psychedelic’ to describe the feelings and sensations associated with an LSD drug reaction. A year later his new word was published and later added to the English lexicon after corresponding with literary genius, Aldous Huxley. In spite of the popular connotations now connected to the word psychedelic, Osmond developed the term out of his experiments with LSD that led him to propose a new theory of schizophrenia alongside a somewhat radical suggestion to treat alcoholism using LSD. In contrast with many of his psychiatric contemporaries, Osmond maintained that pharmacotherapies flourished most when combined with tenets of empathy, deference, and even ritual – features he learned from Indigenous ceremonies with plant medicines. Although Osmond was not alone among his psychiatrist colleagues in the 1950s fascinated with the medical applications of psychedelics, his work in Canada brought him international recognition and made him a major figure in the history of LSD and addiction research, but also an awkward character in a looming countercultural revolution. LSD was banned from use by the late 1960s for a combination of moral and scientific reasons, but new developments in the 21st are encouraging policy makers and researchers to revisit these historical studies. This presentation examines some of the historical Canadian trials with LSD, while it remained a legal substance, and considers how the drug and its supporters dealt with challenges, first from the medical community and later from political and moral authorities concerned about the abusive characteristics of the drug.
This presentation will explore both the psychedelic research renaissance and an analysis of the pending legalization of psychedelics from a business perspective.
Host – Cy Williams